JPMorgan raises Biogen to overweight from neutral, raises target price to $300 from $210
BIIB•JPMorgan raised its rating on Biogen to overweight from neutral and its target price to $300 from $210.
Related News
Brixmor Property Group target price cut to $38 from $42 by Jefferies
BRX•
Iron Mountain target price cut to $135 from $147
IRM•
Mukesh Ambani's ill-timed Jio IPO has some logic
RELI•
AEVEX Corp: RBC cuts target price to $26 from $31
AVEX•
Agree Realty Corporation: Jefferies cuts target price to $74 from $87
ADC•